{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-168907","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.651259+00:00","generated_at":"2026-05-15T04:54:04.694974+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cue Biopharma files 1-for-30 reverse stock split to maintain Nasdaq listing","bullets":["1-for-30 reverse stock split effective 5:00 PM ET on April 23, 2026; no fractional shares, cash in lieu.","Common stock begins trading post-split on April 24 under symbol CUE; new CUSIP 22978P205.","Reverse split aims to meet Nasdaq minimum bid price requirement, as disclosed in proxy statement.","No change in authorized shares ($0.001 par); options and warrants proportionately adjusted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-168907","json":"https://secwatch.observer/filing/0001193125-26-168907.json","markdown":"https://secwatch.observer/filing/0001193125-26-168907.md","text":"https://secwatch.observer/filing/0001193125-26-168907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526168907/0001193125-26-168907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526168907/cue-20260422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:54:04.694974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"212cf731b14bcbe228e7b23c8d0d53f099bc96f0","claim":"Cue Biopharma, Inc.: 1-for-30 reverse stock split effected by filing a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2026-04-23).","evidence_excerpt":"On April 22, 2026, Cue Biopharma, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on April 23, 2026 (the “Effective Time”), a 1-for-30 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526168907/0001193125-26-168907-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-04-23"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}